| Antibodies |
Target Antigen |
Developed by |
Indication |
Status |
| Ipilimumab |
CTLA-4 |
Bristol-Myers Squibb |
Metastatic Melanoma |
FDA approval |
| Bevacizumab |
VEGF-A |
Genentech/Roche |
Metastatic colon cancer |
FDA approval |
| Panorex 17-1A |
EpCAM |
GlaxoSmithKline/Centocor |
Colorectal cancer |
German approval |
| Rituxan |
CD20 |
IDEC Pharm |
Non-Hodgkin’s Lymphoma |
FDA approval |
| Herceptin |
Her2/neu |
Genentech |
Metastatic Breast cancer |
FDA approval |
| MoAb730 |
Tumor antigen on DU145 cell line |
Talwar Research Foundation |
Castration-resistant prostate cancer cells DU145 and PC3 |
Preclinical development |
| MoAb7B2G10 |
Tumor antigen on PC3 cell line |
Talwar Research Foundation |
Castration-resistant prostate cancer cells DU145 and PC3 |
Preclinical development |
| MoAb3C8D4 |
Tumor antigen on PC3 cell line |
Talwar Research Foundation |
Castration-resistant prostate cancer cells DU145 and PC3 |
Preclinical development |
| PiPP |
β subunit of human chorionic gonadotropin (hCGβ) |
Talwar Research Foundation |
Advanced stage cancers ectopically expressing hCG |
Preclinical development |
| PiPP-curcumin conjugate |
β subunit of human chorionic gonadotropin (hCGβ) |
Talwar Research Foundation |
Kills MOLT-4 cells (human T-lymphoblastic leukemia cells) and U-937 cells (histolytic lymphoma cells) |
Preclinical development |
| MoAbCC4 |
Carcinoembryonic antigen (CEA) |
National laboratory of Biomacromolecules, Chinese Academy of Sciences, Beijing |
Colorectal cancer |
Preclinical development |
| Nivolumab |
PD-1 |
Bristol-Myers Squibb |
Renal cell cancer, melanoma, castration resistant prostate cancer, non–small cell lung cancer, colorectal cancer |
Undergone Phase-I trial |
| Lambrolizumab |
PD-1 |
Merck |
Solid cancers |
Undergone Phase-I trial |
| Pidilizumab |
PD-1 |
CureTech Ltd. |
Advanced hematologic Malignancies |
Undergone Phase-I trial |
| MoAb BMS-936559 |
PD-L1 |
Bristol-Myers Squibb |
Non-small-cell lung cancer, melanoma, renal cell carcinoma |
Undergone Phase-I trial |
| Vaccines |
| Sipuleucel-T |
Prostatic acid phosthatase |
Dendreon |
Castration-resistant prostate cancer |
FDA approval |
| Racotumomab |
NeuGcGM3 |
Recombio |
Advanced stage lung cancer |
Argentina and Cuba approval |
| Oncophage |
HSPPC-96 |
Antigenics.Inc. |
Kidney cancer |
Russian approval |
| PANVAC |
Carcinoembryonic antigen (CEA) |
National Institute of Health (NIH), USA |
Ovarian and breast cancers |
Undergone Phase-I trial |
| CEA-LTB |
Carcinoembryonic antigen (CEA) |
Talwar Research Foundation |
Advanced stage cancers ectopically expressing CEA |
Preclinical development |
| ProstVac-VF |
Prostate specific antigen |
National Institute of Health (NIH), USA |
Castration-resistant prostate cancer |
Undergone Phase-I trial |
| CDX-1307 |
β subunit of human chorionic gonadotropin (hCGβ) |
Celldex |
Advanced epithelial cancers expressing hCGβ |
Undergone Phase-I trial |
| hCGβ-LTB |
β subunit of human chorionic gonadotropin (hCGβ) |
Talwar Research Foundation |
Advanced stage cancers ectopically expressing hCGβ |
Ready for clinical trials |
| LHRH-D-Lys-R-N=CH-(CH2)3-CH=N-DT |
Luteinizing-Hormone-Releasing Hormone (LHRH) |
Talwar Research Foundation |
Carcinoma of prostate |
Undergone successfully Phase II trials in 3 centers in India and Austria |
